ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Perceived Diabetes Burden, Clinical Care Gap, and Intent to Prescribe a Diabetes Polypill to Indian Patients with Type 2 Diabetes.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Type 2 diabetes (T2D) is often associated with hypertension and dyslipidemia and is known to increase the risk for cardiovascular disease (CVD). A fixed-dose diabetes polypill, which can lower glycemia, blood pressure, and cholesterol, can improve treatment adherence in patients with T2D. This survey was conducted among healthcare professionals (HCPs) in India to assess the perceived T2D burden, clinical gaps, and intent to prescribe polypill to patients. Methods: The study was conducted in two phases: Phase 1 quantitative online/in-person surveys to assess patient load, proportion of treatment-naïve patients, initiated/current treatment, patients achieving glycemic goals, and intent to prescribe polypill; and Phase 2 quantitative telephonic-aided online surveys to evaluate factors impacting treatment choice, validating polypill concept, and intention to prescribe. Results: Phase 1 survey included 5,000 respondents (3,000 general practitioners [GPs], 1,500 diabetologists, 500 endocrinologists) and Phase 2 survey included 500 respondents (300 GPs, 150 diabetologists, 50 endocrinologists). Approximately 92% of HCPs indicated concern regarding treatment adherence for all risk factors. Treatment goals were reported to be achieved in 67%, 58%, and 52% patients for hyperglycemia, hypertension, and dyslipidemia, respectively. The most preferred pharmacological treatment approach was combination therapy (65%); around 84% of physicians preferred a fixed-dose therapy. Approximately, 79% HCPs believed that polypill demonstrated greater benefits compared to other products, and 86% of HCPs had high intention to prescribe polypill. The survey results indicated that most HCPs preferred fixed-dose therapy, and believed that a fixed-dose diabetes polypill could be beneficial in reducing T2D associated CVD risk factors in patients. Conclusion: Most HCPs considered CVD risk management and adherence to medication as serious challenges and intended to prescribe an affordable and efficacious diabetes polypill to patients with T2D to lower CVD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.